Genetic markers of treatment response in rheumatoid arthritis.
Rheumatoid arthritis patients exhibit a considerable interindividual variability in response to drug treatment. Although many disease-related and demographic factors have been studied to predict treatment outcome, the effective disease-modifying antirheumatic drug (DMARD) therapy is not yet allocated based on factors that predict efficacy. Individual genetic characteristics are thought to play an important role in treatment response; therefore, current research aims to identify these genetic predictors for clinical response. Pharmacogenetic studies are beginning to provide results, which suggests that personalized treatment maximization of DMARD efficacy and minimization of adverse drug reactions are feasible.
Wesoly
Joanna
J
Department of Rheumatology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
Wessels
Judith A M
JA
Guchelaar
Henk-Jan
HJ
Huizinga
Tom W J
TW
D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D015415:Biomarkers / Q000378:metabolism*; D016207:Cytokines / Q000097:blood / Q000187:drug effects / Q000235:genetics*; D004247:DNA / Q000235:genetics*; D006801:Humans; D011379:Prognosis
D018501:Antirheumatic Agents; D015415:Biomarkers; D016207:Cytokines; D004247:DNA